SG10201906599VA - Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereof - Google Patents
Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereofInfo
- Publication number
- SG10201906599VA SG10201906599VA SG10201906599VA SG10201906599VA SG10201906599VA SG 10201906599V A SG10201906599V A SG 10201906599VA SG 10201906599V A SG10201906599V A SG 10201906599VA SG 10201906599V A SG10201906599V A SG 10201906599VA SG 10201906599V A SG10201906599V A SG 10201906599VA
- Authority
- SG
- Singapore
- Prior art keywords
- highly
- obtaining
- composition
- proteinase inhibitor
- concentrated alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713673P | 2018-08-02 | 2018-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201906599VA true SG10201906599VA (en) | 2020-03-30 |
Family
ID=67439017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201906599VA SG10201906599VA (en) | 2018-08-02 | 2019-07-16 | Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11253578B2 (en) |
| EP (1) | EP3632412A1 (en) |
| JP (2) | JP7458717B2 (en) |
| KR (1) | KR20200015409A (en) |
| CN (1) | CN110787297B (en) |
| AR (1) | AR117626A1 (en) |
| AU (1) | AU2019204927A1 (en) |
| BR (1) | BR102019014292A2 (en) |
| CA (1) | CA3049584A1 (en) |
| CL (1) | CL2019002131A1 (en) |
| IL (1) | IL267923B2 (en) |
| MX (1) | MX2019008968A (en) |
| SG (1) | SG10201906599VA (en) |
| UY (1) | UY38315A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL267923B2 (en) | 2018-08-02 | 2023-06-01 | Grifols Worldwide Operations Ltd | Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereof |
| KR20220145352A (en) * | 2020-02-25 | 2022-10-28 | 그리폴즈 월드와이드 오퍼레이션스 리미티드 | Methods for obtaining alpha-1 proteinase inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616693A (en) | 1996-07-01 | 1997-04-01 | Alpha Therapeutic Corporation | Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste |
| US6462180B1 (en) | 1999-11-24 | 2002-10-08 | Bayer Corporation | Method of preparing α-1 proteinase inhibitor |
| AU1344102A (en) | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| SI1345597T1 (en) | 2000-12-27 | 2007-12-31 | Ares Trading Sa | Amphiphilic lipid nanoparticles for peptide and/or protein incorporation |
| US7777006B2 (en) | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| ZA200505306B (en) | 2002-12-31 | 2006-09-27 | Altus Pharmaceuticals Inc | Complexes of protein crystals and ionic polymers |
| EP1664123B2 (en) | 2003-09-22 | 2011-11-30 | Kamada Ltd. | Large scale preparation of alpha-1 proteinase inhibitor and use thereof |
| JP2007534633A (en) | 2003-11-10 | 2007-11-29 | アライバ−プロメティック インコーポレイティド | Human alpha 1-antitrypsin preparation |
| JP2007511539A (en) | 2003-11-14 | 2007-05-10 | バクスター・インターナショナル・インコーポレイテッド | Alpha1-antitrypsin compositions and methods of treatment using such compositions |
| RU2268736C1 (en) | 2004-06-17 | 2006-01-27 | Общество с ограниченной ответственностью "БиоГениус" | Method for production of alpha-1-antitrypsin and product useful in medicine |
| US7384549B2 (en) | 2005-12-29 | 2008-06-10 | Spf Innovations, Llc | Method and apparatus for the filtration of biological solutions |
| ES2611944T3 (en) | 2007-11-02 | 2017-05-11 | Grifols Therapeutics Inc. | Procedure, composition and article of manufacture to provide alpha-1-antitrypsin |
| CN102099369A (en) | 2008-07-18 | 2011-06-15 | 泰勒克里斯生物治疗学公司 | Method of preparing alpha-1 proteinase inhibitor |
| EP2496246B1 (en) | 2009-11-03 | 2018-06-27 | Grifols Therapeutics LLC | Composition, method, and kit for alpha-1 proteinase inhibitor |
| EP4043025A1 (en) * | 2011-06-08 | 2022-08-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| EP2682168A1 (en) | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
| CN103788209B (en) * | 2012-10-29 | 2016-02-24 | 广东双林生物制药有限公司 | A kind of preparation method of Prolastin |
| WO2015195453A2 (en) * | 2014-06-16 | 2015-12-23 | Emd Millipore Corporation | Methods for increasing the capacity of flow-through processes |
| US20170312282A1 (en) * | 2016-04-28 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Tyrosine kinase inhibitor formulations for the treatment of mast cell-mediated inflammatory diseases and methods of use thereof |
| IL267923B2 (en) | 2018-08-02 | 2023-06-01 | Grifols Worldwide Operations Ltd | Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereof |
-
2019
- 2019-07-08 IL IL267923A patent/IL267923B2/en unknown
- 2019-07-09 AU AU2019204927A patent/AU2019204927A1/en active Pending
- 2019-07-10 BR BR102019014292-8A patent/BR102019014292A2/en unknown
- 2019-07-12 CA CA3049584A patent/CA3049584A1/en active Pending
- 2019-07-16 JP JP2019131112A patent/JP7458717B2/en active Active
- 2019-07-16 SG SG10201906599VA patent/SG10201906599VA/en unknown
- 2019-07-19 CN CN201910655484.6A patent/CN110787297B/en active Active
- 2019-07-24 UY UY0001038315A patent/UY38315A/en unknown
- 2019-07-26 EP EP19188500.3A patent/EP3632412A1/en active Pending
- 2019-07-29 AR ARP190102127A patent/AR117626A1/en unknown
- 2019-07-29 MX MX2019008968A patent/MX2019008968A/en unknown
- 2019-07-30 CL CL2019002131A patent/CL2019002131A1/en unknown
- 2019-08-01 KR KR1020190093626A patent/KR20200015409A/en active Search and Examination
- 2019-08-01 US US16/529,686 patent/US11253578B2/en active Active
-
2021
- 2021-09-22 US US17/448,509 patent/US11701412B2/en active Active
-
2023
- 2023-05-12 US US18/316,850 patent/US20230277636A1/en active Pending
-
2024
- 2024-01-24 JP JP2024008737A patent/JP2024040213A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11253578B2 (en) | 2022-02-22 |
| IL267923B2 (en) | 2023-06-01 |
| JP7458717B2 (en) | 2024-04-01 |
| US11701412B2 (en) | 2023-07-18 |
| TW202019945A (en) | 2020-06-01 |
| US20200038494A1 (en) | 2020-02-06 |
| BR102019014292A2 (en) | 2020-02-18 |
| CL2019002131A1 (en) | 2020-03-20 |
| AR117626A1 (en) | 2021-08-18 |
| EP3632412A1 (en) | 2020-04-08 |
| CN110787297A (en) | 2020-02-14 |
| IL267923A (en) | 2020-02-27 |
| UY38315A (en) | 2020-02-28 |
| KR20200015409A (en) | 2020-02-12 |
| CA3049584A1 (en) | 2020-02-02 |
| CN110787297B (en) | 2023-08-18 |
| AU2019204927A1 (en) | 2020-02-20 |
| JP2020019765A (en) | 2020-02-06 |
| US20220000992A1 (en) | 2022-01-06 |
| US20230277636A1 (en) | 2023-09-07 |
| MX2019008968A (en) | 2020-02-03 |
| JP2024040213A (en) | 2024-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282191A (en) | Methods and compositions for editing rnas | |
| IL287248A (en) | Methods and compositions for editing rnas | |
| ZA202002037B (en) | Cap-dependent endonuclease inhibitors | |
| IL282237A (en) | Compositions and methods for treating alpha-1 antitrypsin deficiencey | |
| EP3710549A4 (en) | Composition for conducting material removal operations and method for forming same | |
| IL272281A (en) | Methods and compositions for heterologous reprna immunizations | |
| GB201905559D0 (en) | Composition and method | |
| ZA202007632B (en) | Compositions and methods for treating alpha-1 antitrypsin deficiency | |
| EP3443141A4 (en) | Composition and method for inhibiting corrosion | |
| EP3733894A4 (en) | Electric-resistance-welded steel pipe and manufacturing method for electric-resistance-welded steel pipe | |
| GB201909542D0 (en) | Composition and method | |
| EP3590361A4 (en) | Luteolin-containing composition and method for manufacturing same | |
| EP3891236B8 (en) | Composition and method for metal cmp | |
| SG10201906599VA (en) | Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereof | |
| EP3795374C0 (en) | Tire composition and method for making thereof | |
| EP3645470A4 (en) | Composition and method for inhibiting corrosion and scale | |
| ZA202007755B (en) | Method for preparing coagulation factor xia inhibitor and intermediate thereof | |
| ZA201808553B (en) | Pipe repair composition and method | |
| EP3590360A4 (en) | Lutein-containing composition and method for manufacturing same | |
| GB2579687B (en) | Composition and method | |
| GB201914777D0 (en) | Composition and method | |
| IL256201A (en) | Composition comprising highly-concentrated alpha-1-proteinase inhibitor and method for obtaining thereof | |
| GB201818328D0 (en) | Method and composition | |
| GB201817000D0 (en) | Method and composition | |
| EP3700990A4 (en) | Composition for conducting material removal operations and method for forming same |